Sunshine Biopharma Balance Sheet Health
Financial Health criteria checks 6/6
Sunshine Biopharma has a total shareholder equity of $21.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $27.3M and $6.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$16.29m |
| Equity | US$21.21m |
| Total liabilities | US$6.14m |
| Total assets | US$27.35m |
Recent financial health updates
Recent updates
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching Revenues
Mar 14
Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its Revenues
Jan 29Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A Catch
Sep 12Sunshine Biopharma acquires Nora Pharma for C$30M
Oct 20We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business Growth
Aug 08Sunshine Biopharma reports 1H results
Aug 04Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral Drugs
Apr 17Financial Position Analysis
Short Term Liabilities: SBFM's short term assets ($24.9M) exceed its short term liabilities ($5.6M).
Long Term Liabilities: SBFM's short term assets ($24.9M) exceed its long term liabilities ($587.8K).
Debt to Equity History and Analysis
Debt Level: SBFM is debt free.
Reducing Debt: SBFM currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SBFM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SBFM has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 54.8% each year.